Plasma levels of exosome‐bound Aβs accurately identify Alzheimer’s disease patients

Blood‐based diagnosis of Alzheimer's disease may be the most efficient, non‐invasive, and cost‐saving method. However, in contrast to CSF, the performance of plasma Aβ42/40 ratio is still arguable in AD diagnosis. Recently, exosome‐based biomarkers have been found that is more reliable biomarker especially in blood‐based AD diagnosis. Here, we assessed the performance of plasma levels of exosome‐bound Aβs.